ARYx Therapeutics, Inc. (ARYX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ARYx Therapeutics, Inc. (ARYX) trades at $0.00 with AI Score 39/100 (Grade D). ARYx Therapeutics, Inc. is a healthcare company focused on developing novel therapies using its RetroMetabolic Drug Design technology. Market cap: $16,731, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for ARYX: ARYX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ARYX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ARYX: 1/1 perspectives are bearish.
How is this calculated? →ARYx Therapeutics, Inc. (ARYX) Healthcare & Pipeline Overview
ARYx Therapeutics, Inc. leverages its RetroMetabolic Drug Design technology to develop structurally unique molecules for large, chronic, and oral markets. The company's pipeline features drug candidates like Tecarfarin in Phase III for anticoagulation and Budiodarone in Phase IIb for atrial fibrillation, alongside other therapies for gastrointestinal and psychiatric disorders.
What Is the Investment Thesis for ARYX?
ARYx Therapeutics, Inc. presents a research profile centered on its proprietary RetroMetabolic Drug Design technology, which serves as a foundational value driver for its diverse pipeline. The company's lead candidate, Tecarfarin (ATI-5923), an oral anticoagulant, is in Phase III clinical development, representing a significant near-term catalyst for potential regulatory approval and commercialization. Budiodarone (ATI-2042) in Phase IIb for atrial fibrillation and ATI-7505 also in Phase IIb for multiple GI disorders further diversify its potential revenue streams. The company's focus on large, chronic, and oral markets positions it to address substantial patient populations. However, with a reported market capitalization of 17K and an OTC Other listing, the company faces considerable financing and liquidity risks. Successful clinical trial outcomes, particularly for Tecarfarin, and effective navigation of regulatory pathways are critical growth catalysts. Conversely, clinical failures, intense competition, and challenges in securing future funding represent key risk factors that could impede pipeline progression and market entry.
Based on FMP financials and quantitative analysis
ARYX Key Highlights
- Market Capitalization: $0.00B, indicating a micro-cap or non-reporting entity with limited public market valuation.
- Beta: -7.55, suggesting a highly inverse and volatile relationship with the broader market, potentially influenced by low liquidity on the OTC market.
- Employee Count: 56 employees, reflecting a specialized, small-to-medium sized biotechnology firm.
- Lead Pipeline Asset: Tecarfarin (ATI-5923) is in Phase III clinical development, representing the most advanced drug candidate in the company's portfolio.
- Proprietary Technology: Utilizes RetroMetabolic Drug Design technology, a unique scientific approach to developing novel drug therapies.
Who Are ARYX's Competitors?
ARYX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ARYX's Key Strengths?
- Proprietary RetroMetabolic Drug Design technology offers a unique approach to drug development.
- Diverse clinical pipeline with drug candidates in Phase III, Phase IIb, and Phase I, addressing multiple therapeutic areas.
- Focus on large, chronic, and oral markets, indicating significant potential patient populations.
- Tecarfarin (ATI-5923) in Phase III clinical development represents an advanced asset with potential for near-term commercialization.
What Are ARYX's Weaknesses?
- Reported market capitalization of 17K suggests a very limited or non-existent public market valuation.
- OTC Other listing implies significant challenges related to liquidity, transparency, and investor confidence.
- Negative Beta of -7.55 is highly unusual and may indicate low trading volume or specific market dynamics, rather than true inverse market correlation.
- High research and development costs inherent in the biotech industry, requiring substantial ongoing financing.
What Could Drive ARYX Stock Higher?
- Successful completion of Phase III clinical trials for Tecarfarin (ATI-5923), potentially leading to regulatory submission.
- Positive data readout and advancement of Budiodarone (ATI-2042) from Phase IIb to Phase III clinical development.
- Regulatory submission and potential approval for Tecarfarin (ATI-5923) with health authorities, opening commercialization pathways.
- Continued clinical development and progress of ATI-7505 (Phase IIb) and ATI-9242 (Phase I) through their respective trial stages.
- Potential for strategic partnerships or licensing agreements for pipeline assets, providing non-dilutive funding or market access.
What Are the Key Risks for ARYX?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High risk of clinical trial failures or delays for any of its drug candidates, particularly for the lead Phase III asset, Tecarfarin.
- Inability to secure adequate financing for continued research, development, and potential commercialization given its 17K market cap and OTC listing.
- Intense competition from established pharmaceutical companies developing similar therapies, potentially limiting market share.
- Regulatory hurdles, non-approval of drug candidates by health authorities, or lengthy review processes.
- Challenges associated with OTC Other listing, including low liquidity, limited investor interest, and difficulty in accurate valuation.
What Are the Growth Opportunities for ARYX?
- Growth opportunity 1: **Commercialization of Tecarfarin (ATI-5923)**: Tecarfarin, an oral anticoagulant currently in Phase III clinical development, represents a significant near-term growth opportunity. The market for anticoagulants is substantial, driven by an aging population and increasing prevalence of conditions like atrial fibrillation and venous thromboembolism. Successful completion of Phase III trials and subsequent regulatory approval would allow ARYX to tap into this multi-billion dollar market. Its oral formulation could offer a competitive advantage in patient convenience and adherence, potentially capturing a meaningful share of the market for patients at risk of dangerous blood clots.
- Growth opportunity 2: **Advancement of Budiodarone (ATI-2042)**: Budiodarone, an oral antiarrhythmic agent in Phase IIb clinical development for atrial fibrillation, addresses a critical unmet medical need. Atrial fibrillation affects millions globally, and current treatments often come with significant side effects or limited efficacy. Advancing Budiodarone through successful Phase IIb and into Phase III trials would position ARYX to compete in a large and growing market for arrhythmia management. Positive clinical data could attract strategic partners, accelerating its path to market and expanding its commercial reach.
- Growth opportunity 3: **Expansion of Gastrointestinal Portfolio with ATI-7505**: ATI-7505, an oral prokinetic agent in Phase IIb, targets multiple prevalent gastrointestinal disorders including chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. Each of these conditions represents a large patient population with varying degrees of satisfaction with current therapies. Successfully developing ATI-7505 for even one of these indications could unlock a substantial market opportunity, providing a new therapeutic option for patients and contributing significantly to ARYX's revenue diversification.
- Growth opportunity 4: **Development of Psychiatric Pipeline with ATI-9242**: ATI-9242, an antipsychotic agent in Phase I clinical development for schizophrenia and other psychiatric disorders, offers a long-term growth avenue. The market for psychiatric medications is vast, with ongoing demand for novel treatments that offer improved efficacy and fewer side effects. Successful progression through early-stage trials and into pivotal studies could position ARYX to address a significant patient population suffering from severe mental health conditions, potentially leading to a breakthrough therapy in this underserved area.
- Growth opportunity 5: **Leveraging RetroMetabolic Drug Design Technology**: ARYX's proprietary RetroMetabolic Drug Design technology is a platform that allows for the creation of multiple drug candidates. This technology could be a source of future growth by generating new pipeline assets for various therapeutic areas beyond the current focus. Furthermore, the unique nature of this technology could attract strategic partnerships, collaborations, or licensing agreements with larger pharmaceutical companies seeking innovative drug discovery platforms, providing non-dilutive funding and validation for ARYX's scientific approach.
What Opportunities Does ARYX Have?
- Successful completion of Phase III clinical trials and regulatory approval for Tecarfarin (ATI-5923).
- Advancement of Budiodarone (ATI-2042) and ATI-7505 through later-stage clinical development, expanding market reach.
- Potential for strategic partnerships or licensing agreements for its drug candidates or RetroMetabolic Drug Design technology.
- Expansion of its pipeline through the advancement of discovery-stage programs (ATI-20,000 and ATI-24,000).
What Threats Does ARYX Face?
- High risk of clinical trial failures or delays for any of its drug candidates, which could significantly impact future prospects.
- Intense competition from larger, well-funded pharmaceutical companies developing similar or superior therapies.
- Regulatory hurdles, non-approvals, or lengthy review processes by health authorities.
- Difficulty in securing adequate future financing to fund ongoing research, development, and potential commercialization efforts.
- Intellectual property challenges and potential for patent expiration or invalidation.
What Are ARYX's Competitive Advantages?
- Proprietary RetroMetabolic Drug Design technology, which aims to create safer, more effective drugs by designing structurally unique molecules.
- Diverse clinical pipeline addressing multiple large, chronic therapeutic areas, reducing single-product dependency and spreading risk.
- Advanced clinical stage assets like Tecarfarin (Phase III), offering a potentially shorter path to market compared to early-stage biotechs.
- Expertise in developing oral therapies, which are generally preferred by patients for convenience and adherence, potentially enhancing market adoption.
What Does ARYX Do?
ARYx Therapeutics, Inc., founded in 1997 and headquartered in Fremont, California, is a pharmaceutical company dedicated to the discovery and development of novel therapeutic agents. The company's core strategy revolves around its proprietary RetroMetabolic Drug Design technology, an innovative approach aimed at creating structurally unique molecules that retain the desired efficacy of original drugs while potentially improving their safety profiles. This technology is applied to target large, chronic, and oral markets, addressing significant unmet medical needs. The company's clinical development portfolio is diverse, featuring several drug candidates at various stages. Tecarfarin (ATI-5923), an oral anticoagulant, is currently in Phase III clinical development, targeting patients at risk for dangerous blood clot formation. Another key asset is Budiodarone (ATI-2042), an oral antiarrhythmic agent, which is in Phase IIb clinical development for the treatment of atrial fibrillation, a common form of irregular heartbeat. Beyond cardiovascular indications, ARYX is developing ATI-7505, an oral prokinetic agent, also in Phase IIb clinical development, for a range of gastrointestinal disorders including chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. Furthermore, ATI-9242, an antipsychotic agent, is in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. The company also maintains an early-stage discovery pipeline, focusing on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders, indicating a long-term commitment to expanding its therapeutic reach.
What Products and Services Does ARYX Offer?
- Develops novel drug therapies using proprietary RetroMetabolic Drug Design technology.
- Focuses on treatments for large, chronic, and oral markets.
- Has an oral anticoagulant, Tecarfarin (ATI-5923), in Phase III clinical trials for blood clot prevention.
- Is developing Budiodarone (ATI-2042), an oral antiarrhythmic, currently in Phase IIb for atrial fibrillation.
- Works on ATI-7505, an oral prokinetic agent for various gastrointestinal disorders, in Phase IIb.
- Has an antipsychotic agent, ATI-9242, in Phase I clinical development for schizophrenia.
- Conducts discovery-stage research for metabolic (ATI-20,000) and gastrointestinal (ATI-24,000) disorders.
- Aims to create structurally unique molecules that maintain drug efficacy while potentially improving safety profiles.
How Does ARYX Make Money?
- Future revenue generation from the commercialization and sales of approved drug products, particularly Tecarfarin and Budiodarone.
- Potential for milestone payments and royalties from licensing agreements with larger pharmaceutical partners for its drug candidates or technology.
- Securing non-dilutive funding through grants or strategic collaborations for specific drug development programs.
- Future sales of proprietary drug candidates upon successful clinical development and regulatory approval in target markets.
What Industry Does ARYX Operate In?
ARYx Therapeutics, Inc. operates within the highly competitive and innovation-driven Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector. This industry is characterized by extensive research and development cycles, significant capital requirements, and stringent regulatory oversight. Key market trends include a growing demand for novel therapies for chronic diseases, a preference for oral drug formulations, and the continuous pursuit of drugs with improved efficacy and safety profiles. ARYX positions itself by leveraging its proprietary RetroMetabolic Drug Design technology, aiming to differentiate its drug candidates from existing treatments. The competitive landscape includes large, established pharmaceutical companies with vast resources, as well as numerous smaller biotechnology firms vying for market share in specific therapeutic areas. ARYX's success will depend on its ability to advance its pipeline through clinical trials, secure regulatory approvals, and effectively commercialize its unique drug candidates in these competitive markets.
Who Are ARYX's Key Customers?
- Healthcare providers, including physicians and hospitals, who will prescribe and administer ARYX's approved therapies.
- Patients suffering from chronic conditions such as blood clots, atrial fibrillation, chronic constipation, and schizophrenia, who will use the prescribed medications.
- Pharmaceutical distributors and pharmacies that will stock and dispense ARYX's drug products.
- Potentially, larger pharmaceutical companies through licensing or acquisition of drug candidates or the underlying technology platform.
Company Profile
ARYx Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Fremont, US. ARYX has traded publicly since 2007.
How ARYx Therapeutics, Inc. Is Valued
ARYx Therapeutics, Inc. carries a market capitalization of 17K, placing it in the micro-cap category. Relative to its peer group, ARYX's quantitative score of 39/100 is below the peer average of 66/100.
F-Score 1/9Financial Health
ARYx Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ARYX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary RetroMetabolic Drug Design technology offers a unique approach to drug development.
- Diverse clinical pipeline with drug candidates in Phase III, Phase IIb, and Phase I, addressing multiple therapeutic areas.
- Focus on large, chronic, and oral markets, indicating significant potential patient populations.
- Tecarfarin (ATI-5923) in Phase III clinical development represents an advanced asset with potential for near-term commercialization.
Bear Case
- Reported market capitalization of 17K suggests a very limited or non-existent public market valuation.
- OTC Other listing implies significant challenges related to liquidity, transparency, and investor confidence.
- Negative Beta of -7.55 is highly unusual and may indicate low trading volume or specific market dynamics, rather than true inverse market correlation.
- High research and development costs inherent in the biotech industry, requiring substantial ongoing financing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ARYX Latest News
No recent news available for ARYX.
ARYX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARYX.
Price Targets
Wall Street price target analysis for ARYX.
ARYX MoonshotScore
What does this score mean?
The MoonshotScore rates ARYX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
ARYX OTC Market Information
ARYx Therapeutics, Inc. trades on the OTC Other tier, which is the lowest and most speculative segment of the OTC market. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies are not required to meet minimum financial standards or file regular reports with the SEC. This tier typically includes companies with limited public information, potentially distressed financials, or those that have been delisted from higher tiers. This contrasts sharply with NYSE/NASDAQ, which demand rigorous listing standards, robust financial disclosures, and higher liquidity, offering investors greater transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and financial transparency due to minimal reporting requirements.
- Low trading volume and potential for wide bid-ask spreads, significantly impacting liquidity and price discovery.
- Increased susceptibility to market manipulation due to low float and limited regulatory oversight.
- Difficulty in obtaining reliable valuation metrics due to lack of comparable data and reporting standards.
- Higher risk of delisting or cessation of trading if disclosure requirements are not met or if the company ceases operations.
- Verify the company's current financial statements and reports directly from the company or alternative sources, if available.
- Research the backgrounds and track records of management and board members for any red flags.
- Assess the progress and validity of clinical trials for Tecarfarin, Budiodarone, and other pipeline assets through independent sources.
- Investigate any recent news, press releases, or regulatory filings (if any exist) for material events.
- Understand the competitive landscape for each of ARYX's drug candidates and the market potential.
- Evaluate the company's intellectual property portfolio and patent protection for its RetroMetabolic Drug Design technology.
- Scrutinize the company's capital structure and any recent financing activities, including dilutive events.
- Established in 1997, indicating a relatively long operational history in the biotech sector.
- Has a defined drug pipeline with candidates in Phase III, Phase IIb, and Phase I clinical development, suggesting active R&D.
- Proprietary RetroMetabolic Drug Design technology suggests a unique scientific approach and potential for innovation.
- Headquartered in Fremont, US, a region known for its biotech and pharmaceutical industry presence.
Common Questions About ARYX (Healthcare)
What does ARYx Therapeutics, Inc. do?
ARYx Therapeutics, Inc. is a pharmaceutical company specializing in the discovery and development of novel drug therapies for chronic, oral markets. The company employs its proprietary RetroMetabolic Drug Design technology to create molecules that aim to retain the efficacy of existing drugs while potentially improving safety profiles. Its pipeline includes Tecarfarin, an oral anticoagulant in Phase III development; Budiodarone, an oral antiarrhythmic in Phase IIb; ATI-7505, an oral prokinetic also in Phase IIb for various GI disorders; and ATI-9242, an antipsychotic in Phase I. Additionally, ARYX has early-stage programs for metabolic and gastrointestinal conditions.
What are the key growth opportunities for ARYX in healthcare?
ARYX has several key growth opportunities stemming from its diverse clinical pipeline. The most immediate is the potential commercialization of Tecarfarin (ATI-5923), an oral anticoagulant in Phase III, targeting a large market for blood clot prevention. Further growth could come from the successful advancement of Budiodarone (ATI-2042) through Phase IIb for atrial fibrillation, addressing a significant unmet need in arrhythmia management. The expansion of its gastrointestinal portfolio with ATI-7505, currently in Phase IIb for multiple chronic conditions, also presents substantial market potential. Leveraging its RetroMetabolic Drug Design technology for new drug candidates or strategic partnerships offers additional long-term growth avenues.
What are the main risks for ARYX as an OTC-listed biotech company?
As an OTC-listed biotech company, ARYX faces several significant risks. A primary concern is the inherent uncertainty and high failure rates associated with clinical drug development, particularly for its lead Phase III candidate, Tecarfarin. The company's OTC Other listing implies limited public disclosure and potentially very low liquidity, making it challenging for investors to trade shares and for the company to raise capital. Furthermore, a 17K market capitalization suggests potential difficulties in securing future financing necessary to fund extensive R&D and commercialization efforts. Intense competition from larger, well-funded pharmaceutical companies also poses a substantial threat to market penetration and profitability.
What are the key factors to evaluate for ARYX?
ARYx Therapeutics, Inc. (ARYX) holds an AI score of 39/100 (low). Not financial advice.
How frequently does ARYX data refresh on this page?
ARYX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ARYX's recent stock price performance?
ARYx Therapeutics, Inc. (ARYX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary RetroMetabolic Drug Design technology offers a unique approach to drug development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARYX overvalued or undervalued right now?
Valuing ARYx Therapeutics, Inc. (ARYX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ARYX?
Before investing in ARYx Therapeutics, Inc. (ARYX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Market capitalization of 17K and 'Unknown' disclosure status for OTC market limit comprehensive financial analysis.
- FMP PEER TICKERS were not provided in the source data, limiting the ability to list specific competitors with tickers and names.